Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection
Abstract Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as the first-line choices regarding the treatment of chronic hepatits B. The impact of the two antiviral agents on prognosis of Chronic hepatitis B (CHB) related hepatocellular carcinoma (HCC) remains to be e...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | Infectious Agents and Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13027-018-0191-8 |
| _version_ | 1819083863191715840 |
|---|---|
| author | Min Zhang Dexin Wang Haidong Liu Hui Li |
| author_facet | Min Zhang Dexin Wang Haidong Liu Hui Li |
| author_sort | Min Zhang |
| collection | DOAJ |
| description | Abstract Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as the first-line choices regarding the treatment of chronic hepatits B. The impact of the two antiviral agents on prognosis of Chronic hepatitis B (CHB) related hepatocellular carcinoma (HCC) remains to be explored. We aim to investigate whether CHB-related HCC patients receiving TDF and ETV have a different prognosis. Methods 233 CHB-related compensated cirrhosis patients were divided into groups according to the nucleut(s)ide patients received. The results of TDF and ETV groups were reviewed and compared. The disease-free survival (DFS) and overall survival (OS) of both groups were analyzed and compared. Results 233 CHB-related compensated cirrhosis patients from 2013 October to 2014 November were included in our study. 107 and 126 patients received TDF and ETV monotherapy, respectively. Child-Pugh score, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin level, status of hepatitis B e antigen (HBeAg) and serum HBV DNA level were compared between groups. DFS in TDF-treatment group were significantly longer than it in ETV-treatment group (p < 0.05). multi-variant analysis indicated that TDF duration was significantly associated with lower probability of HCC development, (hazard ratio, 0.35; 95% confidence interval range, 0.33–0.84, p < 0.05). Conclusion Anti-virus regimen containing TDF benefits for the prognosis of CHB-related liver cirrhosis patients. |
| first_indexed | 2024-12-21T20:39:19Z |
| format | Article |
| id | doaj.art-d2e720a778234f58baea4206473708e4 |
| institution | Directory Open Access Journal |
| issn | 1750-9378 |
| language | English |
| last_indexed | 2024-12-21T20:39:19Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Agents and Cancer |
| spelling | doaj.art-d2e720a778234f58baea4206473708e42022-12-21T18:51:01ZengBMCInfectious Agents and Cancer1750-93782018-06-011311610.1186/s13027-018-0191-8Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resectionMin Zhang0Dexin Wang1Haidong Liu2Hui Li3Department of Gastroenterology, Qingdao NO.6 People’s Hospital10th Department of Hepatology, Qingdao NO.6 People’s HospitalDepartment of Gastroenterology, Qingdao NO.6 People’s HospitalInvasive Technology Department, Jining NO.1 People’s HospitalAbstract Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as the first-line choices regarding the treatment of chronic hepatits B. The impact of the two antiviral agents on prognosis of Chronic hepatitis B (CHB) related hepatocellular carcinoma (HCC) remains to be explored. We aim to investigate whether CHB-related HCC patients receiving TDF and ETV have a different prognosis. Methods 233 CHB-related compensated cirrhosis patients were divided into groups according to the nucleut(s)ide patients received. The results of TDF and ETV groups were reviewed and compared. The disease-free survival (DFS) and overall survival (OS) of both groups were analyzed and compared. Results 233 CHB-related compensated cirrhosis patients from 2013 October to 2014 November were included in our study. 107 and 126 patients received TDF and ETV monotherapy, respectively. Child-Pugh score, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin level, status of hepatitis B e antigen (HBeAg) and serum HBV DNA level were compared between groups. DFS in TDF-treatment group were significantly longer than it in ETV-treatment group (p < 0.05). multi-variant analysis indicated that TDF duration was significantly associated with lower probability of HCC development, (hazard ratio, 0.35; 95% confidence interval range, 0.33–0.84, p < 0.05). Conclusion Anti-virus regimen containing TDF benefits for the prognosis of CHB-related liver cirrhosis patients.http://link.springer.com/article/10.1186/s13027-018-0191-8TenofovirEntecavirChronic hepatits BHepatocellular carcinomaNucleus(t)ide analogues |
| spellingShingle | Min Zhang Dexin Wang Haidong Liu Hui Li Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection Infectious Agents and Cancer Tenofovir Entecavir Chronic hepatits B Hepatocellular carcinoma Nucleus(t)ide analogues |
| title | Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection |
| title_full | Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection |
| title_fullStr | Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection |
| title_full_unstemmed | Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection |
| title_short | Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection |
| title_sort | tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis b patients after liver resection |
| topic | Tenofovir Entecavir Chronic hepatits B Hepatocellular carcinoma Nucleus(t)ide analogues |
| url | http://link.springer.com/article/10.1186/s13027-018-0191-8 |
| work_keys_str_mv | AT minzhang tenofovirdecreasehepatocellularcarcinomarecurrenceinchronichepatitisbpatientsafterliverresection AT dexinwang tenofovirdecreasehepatocellularcarcinomarecurrenceinchronichepatitisbpatientsafterliverresection AT haidongliu tenofovirdecreasehepatocellularcarcinomarecurrenceinchronichepatitisbpatientsafterliverresection AT huili tenofovirdecreasehepatocellularcarcinomarecurrenceinchronichepatitisbpatientsafterliverresection |